Auchampach J A, Grover G J, Gross G J
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226.
Cardiovasc Res. 1992 Nov;26(11):1054-62. doi: 10.1093/cvr/26.11.1054.
The aims were: (1) to determine if a new ischaemia selective ATP dependent potassium (KATP) channel antagonist, sodium 5-hydroxydecanoate (5-HD), blocks ischaemic preconditioning in dogs; (2) to determine whether a small intracoronary dose of glibenclamide, a classical sulphonylurea KATP channel antagonist, could block ischaemic preconditioning independent of systemic metabolic effects.
Barbitone anaesthetised dogs were subjected to 60 min of left circumflex coronary artery occlusion followed by 5 h of reperfusion. Preconditioning was produced by a single 5 min left circumflex occlusion followed by 10 min of reperfusion prior to the 60 min occlusion period. 5-HD (150 micrograms.kg-1 x min-1) or vehicle was given by intracoronary infusion into the ischaemic region over 20 min, beginning 15 min prior to the 60 min occlusion period in the presence or absence of preconditioning. Glibenclamide (3 micrograms.kg-1 x min-1) was given by intracoronary infusion into the left circumflex artery during the 5 min preconditioning period or during the first 5 min of occlusion in preconditioned or non-preconditioned dogs. Transmural myocardial blood flow was measured by radioactive microspheres and infarct size determined by triphenyltetrazolium staining and expressed as a percent of the area at risk.
There were no differences in haemodynamic variables, myocardial blood flow, area at risk, or blood glucose between groups. Infarct size was markedly reduced in preconditioned dogs compared to control animals, at 7(SEM 2)% v 29(4)%, p < 0.05 The reduction in infarct size by preconditioning was blocked completely by intracoronary 5-HD, or by intracoronary glibenclamide given during preconditioning or during the first 5 min of the prolonged occlusion period. Neither 5-HD nor glibenclamide affected infarct size in the absence of preconditioning at the doses studied.
These results further strengthen the hypothesis that activation of myocardial KATP channels is involved in the mechanism of ischaemic preconditioning in dogs.
本研究旨在:(1)确定一种新型的缺血选择性ATP依赖性钾(KATP)通道拮抗剂5-羟基癸酸钠(5-HD)是否能阻断犬的缺血预处理;(2)确定冠状动脉内小剂量的格列本脲(一种经典的磺酰脲类KATP通道拮抗剂)是否能独立于全身代谢效应而阻断缺血预处理。
用巴比妥麻醉犬,使其左回旋支冠状动脉闭塞60分钟,随后再灌注5小时。预处理是在60分钟闭塞期之前,通过单次5分钟的左回旋支闭塞,随后再灌注10分钟来实现的。在有或无预处理的情况下,在60分钟闭塞期前15分钟开始,通过冠状动脉内输注将5-HD(150微克·千克⁻¹·分钟⁻¹)或赋形剂在20分钟内注入缺血区域。在5分钟预处理期或预处理及未预处理犬的闭塞最初5分钟内,通过冠状动脉内输注将格列本脲(3微克·千克⁻¹·分钟⁻¹)注入左回旋支动脉。用放射性微球测量跨壁心肌血流量,并用三苯基四氮唑染色法确定梗死面积,并表示为危险区域面积的百分比。
各组之间的血流动力学变量、心肌血流量、危险区域或血糖均无差异。与对照动物相比,预处理犬的梗死面积显著减小,分别为7(标准误2)%和29(4)%,p<0.05。冠状动脉内注射5-HD,或在预处理期间或延长闭塞期的最初5分钟内注射冠状动脉内格列本脲,可完全阻断预处理对梗死面积的减小作用。在所研究的剂量下,5-HD和格列本脲在无预处理时均不影响梗死面积。
这些结果进一步支持了心肌KATP通道激活参与犬缺血预处理机制的假说。